After months of international availability, the Dexcom G7 constant glucose monitor received its FDA clearance to distribute in the US. Ahead of the wide rollout, we got to go hands-on with a demo ...

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that Health Canada ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully ...

Dexcom G7 is the most accurate CGM system1 approved by Health Canada, building on the trusted performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hypoglycemia, and improve time ...

The Dexcom G7 continuous glucose monitoring (CGM) system has been granted a CE Mark (Conformité Européenne), which means it is approved for use in people with diabetes in Europe aged 2 years and older ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA has granted clearance to a next-generation ...

People with Type 1 diabetes are estimated to make up to 180 more decisions a day than someone without the disease, according to a study from Stanford University. Each meal, workout, or night’s sleep ...

New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Ontario residents eligible for ODB and ...

People with Type 1 diabetes are estimated to make up to 180 more decisions a day than someone without the disease, according to a study from Stanford University. Each meal, workout, or night’s sleep ...